Related Experiment Video
Updated: Dec 3, 2025
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
Analysis of dynamic disturbance in blood coagulation function of patients with Coronavirus Disease 2019: A
Nian Chen1, Yuwen Li2, Haozhi Fan3
1Department of Infectious Disease.
Insights
Blood coagulation markers like D-dimer and fibrinogen/fibrin degradation products (FDP) indicate COVID-19 severity. Monitoring these coagulation function indexes aids in early diagnosis and treatment guidance for severe cases.
Area of Science:
- Hematology
- Infectious Diseases
- Critical Care Medicine
Background:
- Coronavirus Disease 2019 (COVID-19) poses a significant threat to global health security.
- Understanding the alterations in blood coagulation function is crucial for managing COVID-19 patients.
- Differences in coagulation parameters may correlate with disease severity.
Purpose of the Study:
- To investigate the differences and dynamic changes in blood coagulation function among COVID-19 patients with varying severity.
- To identify potential biomarkers for assessing COVID-19 patient condition and guiding treatment.
Main Methods:
- Retrospective observational study involving 261 COVID-19 patients.
- Patients categorized into ordinary, severe, and critical subgroups based on national guidelines.
- Collection and comparison of clinical data, including blood routine and coagulation function tests (D-dimer, FDP, platelet count, lymphocyte count).
Main Results:
- Significant differences in D-dimer, FDP, platelet count, and lymphocyte count were observed at admission and during hospitalization across severity groups (P < .05 and P < .001).
- Critical patients were older on average.
- D-dimer and FDP levels showed an initial increase followed by a decrease in severe and critical cases during the disease course.
Conclusions:
- Coagulation function indexes, specifically D-dimer and FDP, can serve as valuable markers for estimating COVID-19 patient condition.
- Close monitoring of coagulation function is beneficial for the early diagnosis of severe COVID-19.
- Coagulation monitoring can aid in guiding therapeutic interventions for COVID-19 patients.
Abstract:
Coronavirus Disease 2019 (COVID-19) has became a major problem affecting global health security.To assess the differences and dynamic changes of blood coagulation function in COVID-19 patients with different severity.A total of 261 COVID-19 patients from January 24 to March 25, 2020 in Huangshi, Hubei Province were enrolled.We designed a retrospective observational study. Clinical information, including age, blood routine and blood coagulation function, were collected. According to the Diagnosis and Treatment Guidelines for COVID-19 (seventh version) that issued by the National Health Committee of the People's Republic of China, patients were divided into 3 subgroups: 186 ordinary, 45 severe and 30 critical ones. We compared the differences in blood coagulation factors among groups.Average age in critical group (71.47 ± 11.48 years) was the oldest of 3 subgroups. At admission, statistically differences could be observed among ordinary, severe and critical patients in D-dimer (0.18 ± 0.33, 0.63 ± 1.13 and 1.16 ± 1.58 mg/L), fibrinogen/fibrin degradation products (FDP) (3.11 ± 5.30, 9.82 ± 23.91 and 21.94 ± 40.98 μg/ml), platelet [(169 ± 62.85), (188 ± 71.56) and (117 ± 38.31) × 10/L)] and lymphocyte count [(1.18 ± 0.46), (0.82 ± 0.35) and (0.75 ± 0.39) × 10/L)], respectively (P < .05). During hospitalization, the peak values of coagulation and valley values of blood routine were monitored. There were significant differences among ordinary, severe and critical patients in D-dimer (0.26 ± 0.46, 1.39 ± 1.51 and 2.89 ± 1.68 mg/L), FDP (3.29 ± 5.52, 23.68 ± 39.07 and 56.11 ± 49.94 μg/ml), platelet [(164 ± 55.53), (171 ± 69.96) and (84 ± 57.80) × 10/L)] and lymphocyte count [(1.10 ± 0.46), (0.65 ± 0.35) and (0.55 ± 0.31) × 10/L)], respectively (P < .001). D-dimer and FDP in the course of disease in severe/critical groups showed a first upward and then downward trend.We concluded that coagulation function indexes such as D-dimer and FDP could be served as markers to estimate COVID-19 patients condition. Close monitoring of coagulation function may be helpful for early diagnosis of severe patients and guidance of treatments.
More Related Videos
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
09:19In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Related Concept Videos
01:06Coagulation
01:09Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins